Sitagliptin Impurity 141 | 36578-37-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Sitagliptin Impurity 141
• 英文别名: N-[2-(2,2-dimethylpropanoylamino)ethyl]-2,2-dimethylpropanamide
• CAS: 36578-37-7
• 化学式: C₁₂H₂₄N₂O₂
• 分子量: 228.33
• InChiKey: JIUXOQPDAVCERS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Chain transfer agents for raft polymerization in aqueous media
  申请人：McCormick L. Charles

  公开号：US20070123670A1

  公开（公告）日：2007-05-31

  Polymers and copolymers synthesized by means that yield a narrow range of molecular weights can have different properties than polymers synthesized by conventional means. In order to obtain such polymers, however, polymerization must be controlled. One type of controlled polymerization is the reversible addition-fragmentation chain transfer (RAFT) process, which has characteristics of a living polymerization. The present invention discloses a group of dithioesters and trithioesters suitable as chain transfer agents for RAFT polymerization. The present invention also discloses RAFT polymerizations conducted in aqueous media.

  通过产生分子量窄范围的手段合成的聚合物和共聚物可能具有不同于传统手段合成的聚合物的性质。然而，为了获得这种聚合物，聚合必须受到控制。一种受控聚合的类型是可逆加成-断裂链转移（RAFT）过程，具有活性聚合的特征。本发明揭示了一组二硫代酯和三硫代酯，适用于RAFT聚合的链转移剂。本发明还揭示了在水介质中进行的RAFT聚合。
• Dimeric compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US10398702B2

  公开（公告）日：2019-09-03

  The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors.

  本发明提供了一种式 I 的化合物，它可作为 SMAC 蛋白与凋亡抑制蛋白（IAPs）结合的抑制剂，和/或活化的 Caspase 蛋白与 IAPs 结合的抑制剂（I）它们的制造、含有它们的药物组合物以及它们作为治疗活性物质的用途，单独或与 DR5/FAP 激动剂抗体联合使用。本发明的活性化合物可用于改善、治疗或控制癌症，尤其是实体瘤。
• Reversal of fosfomycin resistance
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US10980811B2

  公开（公告）日：2021-04-20

  Compounds, pharmaceutical compositions, and methods for reversing fosfomycin resistance are disclosed. Embodiments of the disclosed compounds inhibit fosfomycin-inhibiting enzymes. Some embodiments of the compounds are FosA inhibitors. The disclosed pharmaceutical compositions include (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) a compound, or a pharmaceutically acceptable salt thereof, which inhibits a fosfomycin-inhibiting enzyme. A method of inhibiting growth of a fosfomycin-resistant bacterium includes contacting the bacterium with (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.

  本研究公开了用于逆转磷霉素抗药性的化合物、药物组合物和方法。所公开化合物的实施方案可抑制磷霉素抑制酶。化合物的一些实施方案是 FosA 抑制剂。所公开的药物组合物包括(i)磷霉素或其药学上可接受的盐和(ii)抑制磷霉素抑制酶的化合物或其药学上可接受的盐。抑制耐磷霉素细菌生长的方法包括使细菌与(i)磷霉素或其药学上可接受的盐和(ii)有效量的已公开化合物或其药学上可接受的盐接触。
• DIMERIC COMPOUNDS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20190134050A1

  公开（公告）日：2019-05-09

  The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors.
• SINGLE FLUORESCENT DYE-BASED SEQUENCING METHOD
  申请人：BGI SHENZHEN

  公开号：US20190330693A1

  公开（公告）日：2019-10-31

  Provided is a single fluorescent dye based sequencing method. Moreover, the present invention further provide modified nucleosides and nucleotides, and a kit comprising the nucleoside and/or nucleotide, particularly suitable for the sequencing method of the present invention. Additionally, the present invention further provides uses of the nucleoside, the nucleotide and the kit for sequencing.